Form 4: Cytek Biosciences CEO Wenbin Jiang Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Wenbin Jiang, CEO of Cytek Biosciences, reports the vesting and subsequent tax withholding of restricted stock units, resulting in adjustments to his beneficial ownership of company stock.
Summary
- On May 19, 2025, Cytek Biosciences CEO Wenbin Jiang reported changes in his beneficial ownership of the company's common stock.
- These changes are due to the vesting of restricted stock units (RSUs).
- A portion of the vested shares was withheld by the company to cover tax obligations.
- Specifically, 6,758, 7,854, 14,733 and 19,334 RSUs vested.
- A total of 1,646, 1,913, 3,588 and 4,708 shares were withheld to satisfy tax obligations at a price of $2.69.
- Following these transactions, Jiang's directly held beneficial ownership stands at 5,261,735 shares.
Sentiment
Score: 6
Explanation: The document is neutral in sentiment. It simply reports transactions related to executive compensation. There are no explicit positive or negative implications for the company's performance.
Positives
- The vesting of RSUs is part of a pre-determined compensation plan, aligning the CEO's interests with the company's long-term performance.
Industry Context
This filing is a routine disclosure related to executive compensation and is common for publicly traded companies. It provides transparency regarding the equity holdings of key executives.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units that vest over time to align executive incentives with shareholder value.
- The vesting schedules and tax withholding practices described in the filing are standard practices in the industry.
- Comparable companies such as Agilent, Danaher, and Thermo Fisher Scientific also utilize equity-based compensation for their executives.
Stakeholder Impact
- The vesting of RSUs and the resulting increase in shares held by the CEO could be viewed positively by shareholders as it aligns management's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| May 18, 2022 | Initial vesting date for some of the RSU awards. |
| May 18, 2023 | Vesting date for some of the RSU awards. |
| May 18, 2024 | Vesting date for some of the RSU awards. |
| March 10, 2025 | Vesting date for some of the RSU awards. |
| May 18, 2025 | Vesting date for some of the RSU awards. |
| May 19, 2025 | Date of the reported transactions (vesting and tax withholding). |
| May 21, 2025 | Date of the form filing. |
| March 10, 2026 | Final vesting date for some of the RSU awards. |
Keywords
Cytek Biosciences, CEO, Wenbin Jiang, Beneficial Ownership, Restricted Stock Units, RSU, Vesting, Tax Withholding, Form 4, CTKB
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.